Company: BIAF
Filing Date: 2025-05-23
Form Type: PRER14A
Source: 0001641172-25-012315
Chunk: 75

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-23
Form: PRER14A
Chunk 75
---
 vote, but not to dispose; (ii) 583,130                                              
 shares of Common Stock owned by the Joyce Living Trust; and (iii) an aggregate of 19,999                                                    
 shares of Common Stock issuable upon exercise of warrants held by the Joyce Living Trust                                                    
 that are currently exercisable. Dr. Joyce is co-trustee of the Joyce Living Trust, together                                                 
 with his wife, Joyce M. Joyce, each of whom may act unilaterally with regard to voting and                                                  
 disposition power over the shares held by the Joyce Living Trust. The Joyce Living Trust                                                    
 has an address at 1092 Madeline Street, New Braunfels, Texas 78132.                                                                         |

<div align='center'>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</div>

Related-Party Transactions

In addition to the compensation arrangements with directors and executive officers described under “Executive and Director Compensation,” the following is a description of each transaction since January 1, 2023, and each currently proposed transaction in which:

| ● | the                                                                                           
 Company was or is to be a participant;                                                        |
| ● | the                                                                                           
 amount involved exceeds the lesser of $120,000 or one percent of the average of the Company’s 
 total assets at year end for the last two completed fiscal years; and                         |
| ● | any                                                                                           
 related person had or will have a direct or indirect material interest.                       |

PPLS Acquisition of the Laboratory

On September 18, 2023, the Company’s wholly owned subsidiary, PPLS, consummated the acquisition of the laboratory assets of Village Oaks Pathology Services, P.A., d/b/a Precision Pathology Services, pursuant to the terms of the Asset Purchase Agreement with Village Oaks. As a result of the acquisition, the CAP-accredited, CLIA-certified clinical pathology laboratory is owned by PPLS. Dr. Roby Joyce was the Medical Director and Laboratory Director of the clinical pathology laboratory prior to the acquisition, and he continues to serve as Medical Director and Laboratory Director of PPLS after the acquisition. Founded in 2007 by Dr. Joyce, Village Oaks has provided pathology services to physicians practicing in a variety of outpatient settings. Since September 2021, Village Oaks, under the trade name Precision Pathology Services, had offered CyPath ®Lung for sale as an LDT for the detection of early-stage lung cancer. In addition to CyPath ®Lung, PPLS intends to continue